We examined the CD11b+F4/80+Gr1- myeloid cells in the tumor, representing tumor-associated macrophages (TAMs) as defined by Peranzoni et al., 2010 and Qian et al., 2010 (58, 59) and observed a significantly increased percentage in each of the immunotherapy treatment groups (Figures 4D, E). This evidence concerns the gene ITGAM and neoplasm.